KRAS and non-small cell lung carcinoma: A combinatorial supply of miR-34a and let-7b carried by neutral lipid emulsion or untargeted nanoparticles has been employed in lung cancer using transgenic mice bearing KRAS/TP53 mutant non-small cell lung cancer (NSCLC) cells [117,121].